|
Basic Characteristics of Mutations
|
|
Mutation Site
|
L595F |
|
Mutation Site Sentence
|
We report the case of a heart transplant recipient with UL97 mutation (L595F) ganciclovir-resistant cytomegalovirus colitis who was successfully treated with off-label use of letermovir. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL97 |
|
Standardized Encoding Gene
|
UL97
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Colitis
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
ganciclovir |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
36682771
|
|
Title
|
Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia
|
|
Author
|
Yanase T,Hatano M,Bujo C,Tsuji M,Ishida J,Amiya E,Okamoto K,Ando M,Shimada S,Kinoshita O,Fukushi S,Yamada S,Ono M,Komuro I
|
|
Journal
|
International heart journal
|
|
Journal Info
|
2023 Mar 31;64(1):95-99
|
|
Abstract
|
Currently available anti-cytomegalovirus (CMV) agents are sometimes poorly tolerated, owing to their side effects. Letermovir is a novel anti-CMV drug that is only approved for CMV prophylaxis in hematopoietic stem cell transplant recipients, with fewer side effects. We report the case of a heart transplant recipient with UL97 mutation (L595F) ganciclovir-resistant cytomegalovirus colitis who was successfully treated with off-label use of letermovir. In treating CMV infection or disease with letermovir, a transient rise or lag in the clearance of CMV-DNA polymerase chain reaction levels has been observed. Our case suggests that CMV-pp65 antigenemia can be an additional marker of treatment efficacy.
|
|
Sequence Data
|
-
|